- Home
- TNXP vs RDCM Comparison
TNXP vs RDCM Comparison
Compare TNXP & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- RDCM
- Stock Information
- Founded
- TNXP 2007
- RDCM 1985
- Country
- TNXP United States
- RDCM Israel
- Employees
- TNXP N/A
- RDCM N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- RDCM Computer peripheral equipment
- Sector
- TNXP Health Care
- RDCM Technology
- Exchange
- TNXP Nasdaq
- RDCM Nasdaq
- Market Cap
- TNXP 213.7M
- RDCM 203.7M
- IPO Year
- TNXP N/A
- RDCM 1997
- Fundamental
- Price
- TNXP $18.12
- RDCM $13.12
- Analyst Decision
- TNXP Buy
- RDCM Strong Buy
- Analyst Count
- TNXP 1
- RDCM 1
- Target Price
- TNXP $70.00
- RDCM $18.00
- AVG Volume (30 Days)
- TNXP 734.4K
- RDCM 35.5K
- Earning Date
- TNXP 11-07-2025
- RDCM 11-12-2025
- Dividend Yield
- TNXP N/A
- RDCM N/A
- EPS Growth
- TNXP N/A
- RDCM 79.61
- EPS
- TNXP N/A
- RDCM 0.56
- Revenue
- TNXP $9,831,000.00
- RDCM $66,334,000.00
- Revenue This Year
- TNXP $14.79
- RDCM $18.07
- Revenue Next Year
- TNXP $933.49
- RDCM $11.52
- P/E Ratio
- TNXP N/A
- RDCM $23.58
- Revenue Growth
- TNXP N/A
- RDCM 18.18
- 52 Week Low
- TNXP $6.76
- RDCM $9.88
- 52 Week High
- TNXP $130.00
- RDCM $15.98
- Technical
- Relative Strength Index (RSI)
- TNXP 34.78
- RDCM 40.03
- Support Level
- TNXP $18.53
- RDCM $12.81
- Resistance Level
- TNXP $18.96
- RDCM $13.87
- Average True Range (ATR)
- TNXP 1.05
- RDCM 0.49
- MACD
- TNXP 0.39
- RDCM -0.08
- Stochastic Oscillator
- TNXP 24.31
- RDCM 16.35
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.